These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 10232704

  • 1. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS, Engerman RL.
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [Abstract] [Full Text] [Related]

  • 2. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG, Pugliese G, LaRose LS, Faller AM, Chang K, Province MA, Williamson JR.
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [Abstract] [Full Text] [Related]

  • 3. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL, Kern TS.
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [Abstract] [Full Text] [Related]

  • 4. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL, Kern TS, Larson ME.
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [Abstract] [Full Text] [Related]

  • 5. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
    Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, Larkins RG.
    Diabetologia; 1991 Apr; 34(4):225-31. PubMed ID: 1906023
    [Abstract] [Full Text] [Related]

  • 6. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats.
    Mauer SM, Steffes MW, Azar S, Brown DM.
    Diabetes; 1989 Jul; 38(7):839-46. PubMed ID: 2525493
    [Abstract] [Full Text] [Related]

  • 7. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies.
    Kassab JP, Guillot R, Andre J, Claperon N, Bellon G, Feldmann G, Peyroux J, Sternberg M.
    Biochem Pharmacol; 1994 Aug 30; 48(5):1003-8. PubMed ID: 8093087
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sorbinil does not prevent galactose-induced glomerular capillary basement membrane thickening in the rat.
    Das A, Frank RN, Zhang NL.
    Diabetologia; 1990 Sep 30; 33(9):515-21. PubMed ID: 2123806
    [Abstract] [Full Text] [Related]

  • 12. Renal hemodynamics in experimentally galactosemic dogs and diabetic dogs.
    Kern TS, Engerman RL.
    Metabolism; 1991 May 30; 40(5):450-4. PubMed ID: 1902544
    [Abstract] [Full Text] [Related]

  • 13. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
    McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG.
    Diabetologia; 1991 Oct 30; 34(10):695-701. PubMed ID: 1959701
    [Abstract] [Full Text] [Related]

  • 14. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A, Ku L, Cohen MP.
    Diabetes; 1984 Jun 30; 33(6):604-7. PubMed ID: 6427041
    [Abstract] [Full Text] [Related]

  • 15. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR, Moriarty RJ, Mayer JH.
    Diabetes; 1984 May 30; 33(5):470-6. PubMed ID: 6202576
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aldose reductase activity and basement membrane thickening.
    Frank RN.
    Metabolism; 1986 Apr 30; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [Abstract] [Full Text] [Related]

  • 19. The polyol pathway in retinal microangiopathy.
    Robison WG, Kinoshita JH, Kador PF.
    Drugs; 1986 Apr 30; 32 Suppl 2():19-22. PubMed ID: 3098542
    [Abstract] [Full Text] [Related]

  • 20. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
    Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y.
    Diabetes Res Clin Pract; 1994 Oct 30; 25(3):147-54. PubMed ID: 7851268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.